High diagnostic performance of plasma and cerebrospinal fluid beta-synuclein for sporadic Creutzfeldt-Jakob disease

Ann Clin Transl Neurol. 2023 Oct;10(10):1904-1909. doi: 10.1002/acn3.51873. Epub 2023 Aug 8.

Abstract

Beta-synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. Here we analysed its accuracy in the discrimination between sporadic Creutzfeldt-Jakob disease (n = 150) and non-prion rapidly progressive dementias (n = 106). In cerebrospinal fluid, beta-synuclein performed better than protein 14-3-3 (AUC 0.95 vs. 0.89) and, to a lesser extent, than total tau (AUC 0.92). Further, the diagnostic value of plasma beta-synuclein (AUC 0.91) outperformed that of plasma tau (AUC 0.79) and neurofilament light chain protein (AUC 0.65) and was comparable to that of cerebrospinal fluid biomarkers. Beta-synuclein might represent the first highly accurate blood biomarker for the diagnosis of sporadic Creutzfeldt-Jakob disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 14-3-3 Proteins / cerebrospinal fluid
  • Biomarkers / cerebrospinal fluid
  • Creutzfeldt-Jakob Syndrome* / cerebrospinal fluid
  • Creutzfeldt-Jakob Syndrome* / diagnosis
  • Humans
  • beta-Synuclein

Substances

  • beta-Synuclein
  • 14-3-3 Proteins
  • Biomarkers

Supplementary concepts

  • Creutzfeldt-Jakob Disease, Sporadic

Grants and funding

This work was funded by EU Joint Programme ‐ Neurodegenerative Disease Research grant 01EW2008; Genfi‐Prox grant 01ED2008A; German Federal Ministry of Education and Research grant FTLDc 01GI1007A; Ministero della Salute grant Ricerca Corrente; Ministero dell'Università e della Ricerca (MUR), National Recovery and Resilience Plan (NRRP) project MNESYS grant PE0000006; EU Moodmarker program grant 01EW2008; Roux program of the Martin Luther University Halle‐Wittenberg; Foundation of the State Baden‐Württemberg grant D.3830; German Research Foundation/DFG grant SFB1279; Boehringer Ingelheim Ulm University BioCenter grant D.5009; Thierry Latran foundation grant D.2468; Medical Faculty of Martin‐Luther‐University of Halle‐Wittenberg grant ClinicianScientist‐ProgrammCS22/06.